文献速递炎症性肠病消化道肿瘤与早癌

适应负荷升高增加炎症性肠病的发病风险及不良预后风险

Allostatic load increases the incidence and risk of adverse prognosis in inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2024-08-21

该研究基于英国生物银行326,345名成人和3767例炎症性肠病患者,探讨适应负荷(AL)与炎症性肠病发病风险及预后的关联。高AL生物标志物组合与炎症性肠病、溃疡性结肠炎和克罗恩病风险升高相关,且AL升高与肠切除、结直肠癌和死亡风险增加相关。

要点

  • 高AL生物标志物组合与炎症性肠病风险升高相关(HR 1.19,95%CI 1.08-1.31)。
  • AL生物标志物组合每升高一个四分位,炎症性肠病发病风险递增。
  • AL生物标志物组合升高与炎症性肠病患者肠切除、结直肠癌和死亡风险增加相关。

核心结论

  • 适应负荷升高与炎症性肠病发病风险以及肠切除、结直肠癌和死亡风险相关。

研究设计与样本

  • 研究纳入英国生物银行326,345名成人和3767例炎症性肠病患者,以AL生物标志物组合评估适应负荷,采用Cox回归模型分析其与炎症性肠病发病风险及预后的关联。

主要发现

  • 高AL生物标志物组合与炎症性肠病风险升高相关(HR 1.19,95%CI 1.08-1.31),与溃疡性结肠炎风险升高相关(HR 1.17,95%CI 1.04-1.32),与克罗恩病风险升高相关(HR 1.25,95%CI 1.05-1.49)。
  • 随着AL生物标志物组合升高,炎症性肠病发病风险在四分位2增加12%、四分位3增加20%、四分位4增加37%。
  • 与四分位1相比,炎症性肠病全因死亡风险在四分位2升高54%、四分位3升高72%、四分位4升高82%。
  • 溃疡性结肠炎和克罗恩病中也观察到类似效应。
  • AL生物标志物组合计数增加与炎症性肠病患者的肠切除和结直肠癌风险升高相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Elevated allostatic load (AL) has been associated with the risk and poor prognosis of many chronic diseases. The association between AL and inflammatory bowel disease (IBD) is unknown. AIMS: The aim of this study is to investigate the associations between AL and the risk and prognosis of IBD. METHODS: We included 326,345 adults and 3767 patients with IBD from the UK Biobank. AL served as the exposure, estimated using the AL biomarker panel, with the primary outcomes including the risk and prognosis of IBD. We used Cox regression models to examine the associations. RESULTS: High AL biomarker panel was associated with a greater risk of IBD (hazard ratio: 1.19, 95% CI: 1.08-1.31), ulcerative colitis (1.17, 95%CI: 1.04-1.32), and Crohn's disease (1.25, 95%CI: 1.05-1.49). Risk of developing IBD increased by 12% in quartile 2, 20% in quartile 3, and 37% in quartile 4 as AL biomarker panel increased. The all-cause mortality risk in IBD compared with quartile 1 rose by 54% for quartile 2, 72% for quartile 3, and 82% for quartile 4, as AL biomarker panel increased. Similar effects were also observed for ulcerative colitis and Crohn's disease. An increase in AL biomarker panel count was associated with an elevated risk of intestinal resection and colorectal cancer in IBD. CONCLUSIONS: Increased AL is associated with IBD risk, as well as the risks of intestinal resection, colorectal cancer and mortality.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Zhao J, Xue E, Zhou S, et al. Allostatic load increases the incidence and risk of adverse prognosis in inflammatory bowel disease. Aliment Pharmacol Ther. 2024. PMID: 39166843. doi:10.1111/apt.18217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。